Stock DNA
Pharmaceuticals & Biotechnology
CAD 206 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.18
7.00%
-5.35
Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - May 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
39.69%
0%
39.69%
6 Months
66.79%
0%
66.79%
1 Year
166.07%
0%
166.07%
2 Years
95.2%
0%
95.2%
3 Years
-64.52%
0%
-64.52%
4 Years
-78.05%
0%
-78.05%
5 Years
-61.86%
0%
-61.86%
Theratechnologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.03%
EBIT Growth (5y)
19.11%
EBIT to Interest (avg)
-2.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.18
Sales to Capital Employed (avg)
3.30
Tax Ratio
5.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.26%
ROCE (avg)
26.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.35
EV to EBIT
33.67
EV to EBITDA
24.67
EV to Capital Employed
36.32
EV to Sales
2.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
107.87%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Feb 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 65 Foreign Institutions (32.25%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'25 - YoY
May'25
May'24
Change(%)
Net Sales
24.90
30.00
-17.00%
Operating Profit (PBDIT) excl Other Income
-2.10
7.60
-127.63%
Interest
1.60
3.70
-56.76%
Exceptional Items
-1.50
-1.20
-25.00%
Consolidate Net Profit
-6.30
1.30
-584.62%
Operating Profit Margin (Excl OI)
-112.80%
197.10%
-30.99%
USD in Million.
Net Sales
YoY Growth in quarter ended May 2025 is -17.00% vs 26.05% in May 2024
Consolidated Net Profit
YoY Growth in quarter ended May 2025 is -584.62% vs 109.56% in May 2024
Annual Results Snapshot (Consolidated) - Nov'24
Nov'24
Nov'23
Change(%)
Net Sales
117.10
110.50
5.97%
Operating Profit (PBDIT) excl Other Income
15.10
-8.00
288.75%
Interest
14.30
14.10
1.42%
Exceptional Items
-9.80
-6.90
-42.03%
Consolidate Net Profit
-11.30
-32.40
65.12%
Operating Profit Margin (Excl OI)
96.40%
-112.60%
20.90%
USD in Million.
Net Sales
YoY Growth in year ended Nov 2024 is 5.97% vs 6.56% in Nov 2023
Consolidated Net Profit
YoY Growth in year ended Nov 2024 is 65.12% vs 47.06% in Nov 2023
About Theratechnologies, Inc. 
Theratechnologies, Inc.
Pharmaceuticals & Biotechnology
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.
Company Coordinates 
Company Details
2015 Peel St 5th Floor , MONTREAL QC : H3A 1T8
Registrar Details






